Viewing Study NCT05225259


Ignite Creation Date: 2025-12-24 @ 2:31 PM
Ignite Modification Date: 2026-02-18 @ 1:38 AM
Study NCT ID: NCT05225259
Status: NO_LONGER_AVAILABLE
Last Update Posted: 2024-02-28
First Post: 2022-01-28
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor
Sponsor: Eli Lilly and Company
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Eligibility Module Contacts Locations Module